ArticlePituitary2013
Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas.
Article in Pituitary, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 47 citations in OpenAlex.
- Gamma Knife Radiosurgery (GKRS) for Patients with Prolactinomas: Long-Term Results From a Single-Center Experience.Medical science monitor : international medical journal of experimental and clinical research · 2020Trial
- Loss of pituitary hormone function after stereotactic radiosurgery for pituitary adenomas: mechanisms and management.Journal of neuro-oncology · 2026Review
- Understanding the Radiobiology of Central Nervous System Diseases in the Golden Age of Radiosurgery-Does It Matter?Brain sciences · 2025Review
- Hypopituitarism after gamma knife radiosurgery for pituitary adenomas: long-term results from a single-center experience.BMC cancer · 2024Article
- Stereotactic Radiosurgery Outcomes in Medically and Surgically Failed or Nonsurgical Candidates with Medically Failed Prolactinomas: A Systematic Review and Meta-Analysis.Journal of neurological surgery. Part B, Skull base · 2023Article
- Article
- Frequency, pattern, and outcome of recurrences after gamma knife radiosurgery for pituitary adenomas.Endocrine · 2017Article
- Target delineation and optimal radiosurgical dose for pituitary tumors.Radiation oncology (London, England) · 2016Review
- Gamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results.Pituitary · 2015Article
- Management of macroprolactinomas.Clinical diabetes and endocrinology · 2015Article
- The biology of radiosurgery and its clinical applications for brain tumors.Neuro-oncology · 2015Review
- Cranial stereotactic radiosurgery: current status of the initial paradigm shifter.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Review
- Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy.Journal of neuro-oncology · 2014Review
- Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy.Journal of neuro-oncology · 2014Review
- Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.Archives of endocrinology and metabolismReview
- Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the efficacy of Gamma knife stereotactic radiosurgery (GKSR) as an adjunctive management modality for patients with drug resistant or intolerant cavernous sinus invasive prolactinomas. Twenty-two patients with cavernous sinus invasive prolactinoma underwent GKSR between 1994 and 2009. Thirteen patients were dopamine agonist (DA) resistant. Six patients were intolerant to DA. Three patients chose GKSR as their initial treatment modality in hopes they might avoid life long suppression medication. The median tumor volume was 3.0 cm3 (range 0.3–11.6). The marginal tumor dose (median= 15 Gy, range 12–25 Gy) prescribed was based on the dose delivered to the optic apparatus. The median follow-up interval was 36 months (range, 12–185). Endocrine normalization was defined as a normal serum prolactin level off DA (cure) or on DA. Endocrine improvement was defined asa decreased but still elevated serum prolactin level. Endocrine deterioration was defined as an increased serum prolactin level. Endocrine normalization was achieved in six(27.3%) patients. Twelve (54.5%) patients had endocrine improvement. Four patients (18.2%) developed delayed increased prolactin. Imaging-defined local tumor control was achieved in 19 (86.4%) patients, 12 of whom had tumor regression. Three patients had a delayed tumor progression and required additional management. One patient developed a new pituitary axis deficiency after GKSR. Invasive prolactinomas continue to pose management challenges. GKSR is a non invasive adjunctive option that may reduce prolactin levels in patients who are resistant to or intolerant of suppression medication. In a minority of cases, patients may no longer require long term suppression therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.